1 PHYSICAL GROWTH DURING THE FIRST YEAR OF LIFE OF INFANTS A LONGITUDINAL STUDY IN ONE RURAL AND ONE URBAN AREA OF HANOI VIETNAM

Huong Nguyen Thu,B. Eriksson,L. Thanh,Chuc Nguyen Thi Kim,M. Petzold,G. Bondjers,H. Ascher

Abstract:

What problem does this paper attempt to address?

Understanding Post-Acute Sequelae of SARS-CoV-2 Infection Through Data-Driven Analysis with the Longitudinal Electronic Health Records: Findings from the RECOVER Initiative

Chengxi Zang,Yongkang Zhang,Jie Xu,Jiang Bian,Dmitry Morozyuk,Edward J. Schenck,Dhruv Khullar,Anna S. Nordvig,Elizabeth A. Shenkman,Russel L. Rothman,Jason P. Block,Kristin Lyman,Mark Weiner,Thomas W. Carton,Fei Wang,Rainu Kaushal

DOI: https://doi.org/10.1101/2022.05.21.22275420

2022-01-01

Abstract:Recent studies have investigated post-acute sequelae of SARS-CoV-2 infection (PASC) using real-world patient data such as electronic health records (EHR). Prior studies have typically been conducted on patient cohorts with small sample sizes1 or specific patient populations2,3 limiting generalizability. This study aims to characterize PASC using the EHR data warehouses from two large national patient-centered clinical research networks (PCORnet), INSIGHT and OneFlorida+, which include 11 million patients in New York City (NYC) and 16.8 million patients in Florida respectively. With a high-throughput causal inference pipeline using high-dimensional inverse propensity score adjustment, we identified a broad list of diagnoses and medications with significantly higher incidence 30-180 days after the laboratory-confirmed SARS-CoV-2 infection compared to non-infected patients. We found more PASC diagnoses and a higher risk of PASC in NYC than in Florida, which highlights the heterogeneity of PASC in different populations.
Postacute Sequelae of SARS-CoV-2 in Children

Suchitra Rao,Rachel S. Gross,Sindhu Mohandas,Cheryl R. Stein,Abigail Case,Benard Dreyer,Nathan M. Pajor,H. Timothy Bunnell,David Warburton,Elizabeth Berg,Jonathan B. Overdevest,Mark Gorelik,Joshua Milner,Sejal Saxena,Ravi Jhaveri,John C. Wood,Kyung E. Rhee,Rebecca Letts,Christine Maughan,Nick Guthe,Leah Castro-Baucom,Melissa S. Stockwell

DOI: https://doi.org/10.1542/peds.2023-062570

2024-02-07

PEDIATRICS

Abstract:The coronavirus disease 2019 (COVID-19) pandemic has caused significant medical, social, and economic impacts globally, both in the short and long term. Although most individuals recover within a few days or weeks from an acute infection, some experience longer lasting effects. Data regarding the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) in children, or long COVID, are only just emerging in the literature. These symptoms and conditions may reflect persistent symptoms from acute infection (eg, cough, headaches, fatigue, and loss of taste and smell), new symptoms like dizziness, or exacerbation of underlying conditions. Children may develop conditions de novo, including postural orthostatic tachycardia syndrome, myalgic encephalomyelitis/chronic fatigue syndrome, autoimmune conditions and multisystem inflammatory syndrome in children. This state-of-the-art narrative review provides a summary of our current knowledge about PASC in children, including prevalence, epidemiology, risk factors, clinical characteristics, underlying mechanisms, and functional outcomes, as well as a conceptual framework for PASC based on the current National Institutes of Health definition. We highlight the pediatric components of the National Institutes of Health-funded Researching COVID to Enhance Recovery Initiative, which seeks to characterize the natural history, mechanisms, and long-term health effects of PASC in children and young adults to inform future treatment and prevention efforts. These initiatives include electronic health record cohorts, which offer rapid assessments at scale with geographical and demographic diversity, as well as longitudinal prospective observational cohorts, to estimate disease burden, illness trajectory, pathobiology, and clinical manifestations and outcomes.

pediatrics
Characterizing Long COVID in Children and Adolescents

Rachel S Gross,Tanayott Thaweethai,Lawrence C Kleinman,Jessica N Snowden,Erika B Rosenzweig,Joshua D Milner,Kelan G Tantisira,Kyung E Rhee,Terry L Jernigan,Patricia A Kinser,Amy L Salisbury,David Warburton,Sindhu Mohandas,John C Wood,Jane W Newburger,Dongngan T Truong,Valerie J Flaherman,Torri D Metz,Elizabeth W Karlson,Lori B Chibnik,Deepti B Pant,Aparna Krishnamoorthy,Richard Gallagher,Michelle F Lamendola-Essel,Denise C Hasson,Stuart D Katz,Shonna Yin,Benard P Dreyer,Megan Carmilani,K Coombs,Megan L Fitzgerald,Nick Güthe,Mady Hornig,Rebecca J Letts,Aimee K Peddie,Brittany D Taylor,Andrea S Foulkes,Melissa S Stockwell,RECOVER-Pediatrics Consortium,RECOVER-Pediatrics Group Authors,Venkataraman Balaraman,Amanda Bogie,Hulya Bukulmez,Allen J Dozor,Daniel Eckrich,Amy J Elliott,Danielle N Evans,Jonathan S Farkas,E Vincent S Faustino,Laura Fischer,Sunanda Gaur,Ashraf S Harahsheh,Uzma N Hasan,Daniel S Hsia,Gredia Huerta-Montañez,Kathy D Hummel,Matt P Kadish,David C Kaelber,Sankaran Krishnan,Jessica S Kosut,Jerry Larrabee,Peter Paul C Lim,Ian C Michelow,Carlos R Oliveira,Hengameh Raissy,Zaira Rosario-Pabon,Judith L Ross,Alice I Sato,Michelle D Stevenson,Maria M Talavera-Barber,Ronald J Teufel,Kathryn E Weakley,Emily Zimmerman,Marie-Abele C Bind,James Chan,Zoe Guan,Richard E Morse,Harrison T Reeder,Natascha Akshoomoff,Judy L Aschner,Rakesh Bhattacharjee,Lesley A Cottrell,Kelly Cowan,Viren A D'Sa,Alexander G Fiks,Maria L Gennaro,Katherine Irby,Manaswitha Khare,Jeremy Landeo Guttierrez,Russell J McCulloh,Shalu Narang,Manette Ness-Cochinwala,Sheila Nolan,Paul Palumbo,Julie Ryu,Juan C Salazar,Rangaraj Selvarangan,Cheryl R Stein,Alan Werzberger,William T Zempsky,Robin Aupperle,Fiona C Baker,Marie T Banich,Deanna M Barch,Arielle Baskin-Sommers,James M Bjork,Susan Y Bookheimer,Sandra A Brown,B J Casey,Linda Chang,Duncan B Clark,Anders M Dale,Mirella Dapretto,Thomas M Ernst,Damien A Fair,Sarah W Feldstein Ewing,John J Foxe,Edward G Freedman,Naomi P Friedman,Hugh Garavan,Dylan G Gee,Raul Gonzalez,Kevin M Gray,Mary M Heitzeg,Megan M Herting,Joanna Jacobus,Angela R Laird,Christine L Larson,Krista M Lisdahl,Monica Luciana,Beatriz Luna,Pamela A F Madden,Erin C McGlade,Eva M Müller-Oehring,Bonnie J Nagel,Michael C Neale,Martin P Paulus,Alexandra S Potter,Perry F Renshaw,Elizabeth R Sowell,Lindsay M Squeglia,Susan Tapert,Lucina Q Uddin,Sylia Wilson,Deborah A Yurgelun-Todd

DOI: https://doi.org/10.1001/jama.2024.12747

IF: 11.816

2024-08-21

JAMA

Abstract:Importance: Most research to understand postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, has focused on adults, with less known about this complex condition in children. Research is needed to characterize pediatric PASC to enable studies of underlying mechanisms that will guide future treatment. Objective: To identify the most common prolonged symptoms experienced by children (aged 6 to 17 years) after SARS-CoV-2 infection, how these symptoms differ by age (school-age [6-11 years] vs adolescents [12-17 years]), how they cluster into distinct phenotypes, and what symptoms in combination could be used as an empirically derived index to assist researchers to study the likely presence of PASC. Design, setting, and participants: Multicenter longitudinal observational cohort study with participants recruited from more than 60 US health care and community settings between March 2022 and December 2023, including school-age children and adolescents with and without SARS-CoV-2 infection history. Exposure: SARS-CoV-2 infection. Main outcomes and measures: PASC and 89 prolonged symptoms across 9 symptom domains. Results: A total of 898 school-age children (751 with previous SARS-CoV-2 infection [referred to as infected] and 147 without [referred to as uninfected]; mean age, 8.6 years; 49% female; 11% were Black or African American, 34% were Hispanic, Latino, or Spanish, and 60% were White) and 4469 adolescents (3109 infected and 1360 uninfected; mean age, 14.8 years; 48% female; 13% were Black or African American, 21% were Hispanic, Latino, or Spanish, and 73% were White) were included. Median time between first infection and symptom survey was 506 days for school-age children and 556 days for adolescents. In models adjusted for sex and race and ethnicity, 14 symptoms in both school-age children and adolescents were more common in those with SARS-CoV-2 infection history compared with those without infection history, with 4 additional symptoms in school-age children only and 3 in adolescents only. These symptoms affected almost every organ system. Combinations of symptoms most associated with infection history were identified to form a PASC research index for each age group; these indices correlated with poorer overall health and quality of life. The index emphasizes neurocognitive, pain, and gastrointestinal symptoms in school-age children but change or loss in smell or taste, pain, and fatigue/malaise-related symptoms in adolescents. Clustering analyses identified 4 PASC symptom phenotypes in school-age children and 3 in adolescents. Conclusions and relevance: This study developed research indices for characterizing PASC in children and adolescents. Symptom patterns were similar but distinguishable between the 2 groups, highlighting the importance of characterizing PASC separately for these age ranges.
Symptoms and risk factors for long COVID in non-hospitalized adults

Anuradhaa Subramanian,Krishnarajah Nirantharakumar,Sarah Hughes,Puja Myles,Tim Williams,Krishna M. Gokhale,Tom Taverner,Joht Singh Chandan,Kirsty Brown,Nikita Simms-Williams,Anoop D. Shah,Megha Singh,Farah Kidy,Kelvin Okoth,Richard Hotham,Nasir Bashir,Neil Cockburn,Siang Ing Lee,Grace M. Turner,Georgios V. Gkoutos,Olalekan Lee Aiyegbusi,Christel McMullan,Alastair K. Denniston,Elizabeth Sapey,Janet M. Lord,David C. Wraith,Edward Leggett,Clare Iles,Tom Marshall,Malcolm J. Price,Steven Marwaha,Elin Haf Davies,Louise J. Jackson,Karen L. Matthews,Jenny Camaradou,Melanie Calvert,Shamil Haroon

DOI: https://doi.org/10.1038/s41591-022-01909-w

IF: 82.9

2022-07-26

Nature Medicine

Abstract:Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinical Practice Research Datalink Aurum, to determine symptoms that are associated with confirmed SARS-CoV-2 infection beyond 12 weeks in non-hospitalized adults and the risk factors associated with developing persistent symptoms. We selected 486,149 adults with confirmed SARS-CoV-2 infection and 1,944,580 propensity score-matched adults with no recorded evidence of SARS-CoV-2 infection. Outcomes included 115 individual symptoms, as well as long COVID, defined as a composite outcome of 33 symptoms by the World Health Organization clinical case definition. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for the outcomes. A total of 62 symptoms were significantly associated with SARS-CoV-2 infection after 12 weeks. The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02–8.39), hair loss (3.99, 3.63–4.39), sneezing (2.77, 1.40–5.50), ejaculation difficulty (2.63, 1.61–4.28) and reduced libido (2.36, 1.61–3.47). Among the cohort of patients infected with SARS-CoV-2, risk factors for long COVID included female sex, belonging to an ethnic minority, socioeconomic deprivation, smoking, obesity and a wide range of comorbidities. The risk of developing long COVID was also found to be increased along a gradient of decreasing age. SARS-CoV-2 infection is associated with a plethora of symptoms that are associated with a range of sociodemographic and clinical risk factors.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Risk Factors Associated with Post-Acute Sequelae of SARS-CoV-2 in an EHR Cohort: A National COVID Cohort Collaborative (N3C) Analysis as part of the NIH RECOVER program

Elaine Hill,Hemal Mehta,Suchetha Sharma,Klint Mane,Catherine Xie,Emily Cathey,Johanna Loomba,Seth Russell,Heidi Spratt,Peter E DeWitt,Nariman Ammar,Charisse Madlock-Brown,Donald Brown,Julie A McMurry,Christopher G Chute,Melissa A Haendel,Richard Moffitt,Emily R Pfaff,Tellen D Bennett,N3C Consortium,RECOVER Consortium

DOI: https://doi.org/10.1101/2022.08.15.22278603

2022-08-17

MedRxiv

Abstract:Background: More than one-third of individuals experience post-acute sequelae of SARS-CoV-2 infection (PASC, which includes long-COVID). Objective: To identify risk factors associated with PASC/long-COVID. Design: Retrospective case-control study. Setting: 31 health systems in the United States from the National COVID Cohort Collaborative (N3C). Patients: 8,325 individuals with PASC (defined by the presence of the International Classification of Diseases, version 10 code U09.9 or a long-COVID clinic visit) matched to 41,625 controls within the same health system. Measurements: Risk factors included demographics, comorbidities, and treatment and acute characteristics related to COVID-19. Multivariable logistic regression, random forest, and XGBoost were used to determine the associations between risk factors and PASC. Results: Among 8,325 individuals with PASC, the majority were >50 years of age (56.6%), female (62.8%), and non-Hispanic White (68.6%). In logistic regression, middle-age categories (40 to 69 years; OR ranging from 2.32 to 2.58), female sex (OR 1.4, 95% CI 1.33-1.48), hospitalization associated with COVID-19 (OR 3.8, 95% CI 3.05-4.73), long (8-30 days, OR 1.69, 95% CI 1.31-2.17) or extended hospital stay (30+ days, OR 3.38, 95% CI 2.45-4.67), receipt of mechanical ventilation (OR 1.44, 95% CI 1.18-1.74), and several comorbidities including depression (OR 1.50, 95% CI 1.40-1.60), chronic lung disease (OR 1.63, 95% CI 1.53-1.74), and obesity (OR 1.23, 95% CI 1.16-1.3) were associated with increased likelihood of PASC diagnosis or care at a long-COVID clinic. Characteristics associated with a lower likelihood of PASC diagnosis or care at a long-COVID clinic included younger age (18 to 29 years), male sex, non-Hispanic Black race, and comorbidities such as substance abuse, cardiomyopathy, psychosis, and dementia. More doctors per capita in the county of residence was associated with an increased likelihood of PASC diagnosis or care at a long-COVID clinic. Our findings were consistent in sensitivity analyses using a variety of analytic techniques and approaches to select controls. Conclusions: This national study identified important risk factors for PASC such as middle age, severe COVID-19 disease, and specific comorbidities. Further clinical and epidemiological research is needed to better understand underlying mechanisms and the potential role of vaccines and therapeutics in altering PASC course.
Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Amy D. Proal,Michael B. VanElzakker

DOI: https://doi.org/10.3389/fmicb.2021.698169

IF: 5.2

2021-06-23

Frontiers in Microbiology

Abstract:The novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic of coronavirus disease 2019 (COVID-19). Across the globe, a subset of patients who sustain an acute SARS-CoV-2 infection are developing a wide range of persistent symptoms that do not resolve over the course of many months. These patients are being given the diagnosis Long COVID or Post-acute sequelae of COVID-19 (PASC). It is likely that individual patients with a PASC diagnosis have different underlying biological factors driving their symptoms, none of which are mutually exclusive. This paper details mechanisms by which RNA viruses beyond just SARS-CoV-2 have be connected to long-term health consequences. It also reviews literature on acute COVID-19 and other virus-initiated chronic syndromes such as post-Ebola syndrome or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) to discuss different scenarios for PASC symptom development. Potential contributors to PASC symptoms include consequences from acute SARS-CoV-2 injury to one or multiple organs, persistent reservoirs of SARS-CoV-2 in certain tissues, re-activation of neurotrophic pathogens such as herpesviruses under conditions of COVID-19 immune dysregulation, SARS-CoV-2 interactions with host microbiome/virome communities, clotting/coagulation issues, dysfunctional brainstem/vagus nerve signaling, ongoing activity of primed immune cells, and autoimmunity due to molecular mimicry between pathogen and host proteins. The individualized nature of PASC symptoms suggests that different therapeutic approaches may be required to best manage care for specific patients with the diagnosis.

microbiology
Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study

Elaine L Hill,Hemalkumar B Mehta,Suchetha Sharma,Klint Mane,Sharad Kumar Singh,Catherine Xie,Emily Cathey,Johanna Loomba,Seth Russell,Heidi Spratt,Peter E DeWitt,Nariman Ammar,Charisse Madlock-Brown,Donald Brown,Julie A McMurry,Christopher G Chute,Melissa A Haendel,Richard Moffitt,Emily R Pfaff,Tellen D Bennett,N3C Consortium,and the RECOVER Consortium

DOI: https://doi.org/10.1186/s12889-023-16916-w

IF: 4.5

2023-10-25

BMC Public Health

Abstract:Background: More than one-third of individuals experience post-acute sequelae of SARS-CoV-2 infection (PASC, which includes long-COVID). The objective is to identify risk factors associated with PASC/long-COVID diagnosis. Methods: This was a retrospective case-control study including 31 health systems in the United States from the National COVID Cohort Collaborative (N3C). 8,325 individuals with PASC (defined by the presence of the International Classification of Diseases, version 10 code U09.9 or a long-COVID clinic visit) matched to 41,625 controls within the same health system and COVID index date within ± 45 days of the corresponding case's earliest COVID index date. Measurements of risk factors included demographics, comorbidities, treatment and acute characteristics related to COVID-19. Multivariable logistic regression, random forest, and XGBoost were used to determine the associations between risk factors and PASC. Results: Among 8,325 individuals with PASC, the majority were > 50 years of age (56.6%), female (62.8%), and non-Hispanic White (68.6%). In logistic regression, middle-age categories (40 to 69 years; OR ranging from 2.32 to 2.58), female sex (OR 1.4, 95% CI 1.33-1.48), hospitalization associated with COVID-19 (OR 3.8, 95% CI 3.05-4.73), long (8-30 days, OR 1.69, 95% CI 1.31-2.17) or extended hospital stay (30 + days, OR 3.38, 95% CI 2.45-4.67), receipt of mechanical ventilation (OR 1.44, 95% CI 1.18-1.74), and several comorbidities including depression (OR 1.50, 95% CI 1.40-1.60), chronic lung disease (OR 1.63, 95% CI 1.53-1.74), and obesity (OR 1.23, 95% CI 1.16-1.3) were associated with increased likelihood of PASC diagnosis or care at a long-COVID clinic. Characteristics associated with a lower likelihood of PASC diagnosis or care at a long-COVID clinic included younger age (18 to 29 years), male sex, non-Hispanic Black race, and comorbidities such as substance abuse, cardiomyopathy, psychosis, and dementia. More doctors per capita in the county of residence was associated with an increased likelihood of PASC diagnosis or care at a long-COVID clinic. Our findings were consistent in sensitivity analyses using a variety of analytic techniques and approaches to select controls. Conclusions: This national study identified important risk factors for PASC diagnosis such as middle age, severe COVID-19 disease, and specific comorbidities. Further clinical and epidemiological research is needed to better understand underlying mechanisms and the potential role of vaccines and therapeutics in altering PASC course.
Attributes and predictors of long COVID

Carole H. Sudre,Benjamin Murray,Thomas Varsavsky,Mark S. Graham,Rose S. Penfold,Ruth C. Bowyer,Joan Capdevila Pujol,Kerstin Klaser,Michela Antonelli,Liane S. Canas,Erika Molteni,Marc Modat,M. Jorge Cardoso,Anna May,Sajaysurya Ganesh,Richard Davies,Long H. Nguyen,David A. Drew,Christina M. Astley,Amit D. Joshi,Jordi Merino,Neli Tsereteli,Tove Fall,Maria F. Gomez,Emma L. Duncan,Cristina Menni,Frances M. K. Williams,Paul W. Franks,Andrew T. Chan,Jonathan Wolf,Sebastien Ourselin,Tim Spector,Claire J. Steves

DOI: https://doi.org/10.1038/s41591-021-01292-y

IF: 82.9

2021-03-10

Nature Medicine

Abstract:Reports of long-lasting coronavirus disease 2019 (COVID-19) symptoms, the so-called 'long COVID', are rising but little is known about prevalence, risk factors or whether it is possible to predict a protracted course early in the disease. We analyzed data from 4,182 incident cases of COVID-19 in which individuals self-reported their symptoms prospectively in the COVID Symptom Study app<sup><a href="/articles/s41591-021-01292-y#ref-CR1">1</a></sup>. A total of 558 (13.3%) participants reported symptoms lasting ≥28 days, 189 (4.5%) for ≥8 weeks and 95 (2.3%) for ≥12 weeks. Long COVID was characterized by symptoms of fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body mass index and female sex. Experiencing more than five symptoms during the first week of illness was associated with long COVID (odds ratio = 3.53 (2.76–4.50)). A simple model to distinguish between short COVID and long COVID at 7 days (total sample size, <i>n</i> = 2,149) showed an area under the curve of the receiver operating characteristic curve of 76%, with replication in an independent sample of 2,472 individuals who were positive for severe acute respiratory syndrome coronavirus 2. This model could be used to identify individuals at risk of long COVID for trials of prevention or treatment and to plan education and rehabilitation services.

biochemistry & molecular biology,cell biology,medicine, research & experimental
X-ray treatment of otosalpingitis.

G. Aschan,B. Nohrman

DOI: https://doi.org/10.3109/00016485709130309

IF: 1.698

Acta Oto-Laryngologica

Abstract:Ever since Crowe (1939) and Burman (1940) introduced radium therapy with applicators in the nasopharynx and published their very favourable results, this form of treatment in cases of impaired tubar passage has been the subject of much discussion. It is a fact that while other advances in oto-rhinology have rapidly won international recognition, this treatment has not been so generally accepted. At the meeting of the American Academy of Ophthalmology and Oto-laryngology in October 1949, a symposium on “Irradiation of Lymphoid Tissue in the Nasopharynx” reflected in the clearest possible way the very contradictory opinions that exist on this subject. There was a great divergency of views, and the results reported by different workers were quite contradictory. Bordley, for instance, spoke very warmly in favour of the application of radium in the nasopharynx, while Guild was extremely sceptical and critical.
Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative

Chengxi Zang,Yongkang Zhang,Jie Xu,Jiang Bian,Dmitry Morozyuk,Edward J. Schenck,Dhruv Khullar,Anna S. Nordvig,Elizabeth A. Shenkman,Russell L. Rothman,Jason P. Block,Kristin Lyman,Mark G. Weiner,Thomas W. Carton,Fei Wang,Rainu Kaushal

DOI: https://doi.org/10.1038/s41467-023-37653-z

IF: 16.6

2023-04-08

Nature Communications

Abstract:Recent studies have investigated post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID) using real-world patient data such as electronic health records (EHR). Prior studies have typically been conducted on patient cohorts with specific patient populations which makes their generalizability unclear. This study aims to characterize PASC using the EHR data warehouses from two large Patient-Centered Clinical Research Networks (PCORnet), INSIGHT and OneFlorida+, which include 11 million patients in New York City (NYC) area and 16.8 million patients in Florida respectively. With a high-throughput screening pipeline based on propensity score and inverse probability of treatment weighting, we identified a broad list of diagnoses and medications which exhibited significantly higher incidence risk for patients 30–180 days after the laboratory-confirmed SARS-CoV-2 infection compared to non-infected patients. We identified more PASC diagnoses in NYC than in Florida regarding our screening criteria, and conditions including dementia, hair loss, pressure ulcers, pulmonary fibrosis, dyspnea, pulmonary embolism, chest pain, abnormal heartbeat, malaise, and fatigue, were replicated across both cohorts. Our analyses highlight potentially heterogeneous risks of PASC in different populations.

multidisciplinary sciences
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19

Michael J Peluso,J Daniel Kelly,Scott Lu,Sarah A Goldberg,Michelle C Davidson,Sujata Mathur,Matthew S Durstenfeld,Matthew A Spinelli,Rebecca Hoh,Viva Tai,Emily A Fehrman,Leonel Torres,Yanel Hernandez,Meghann C Williams,Mireya I Arreguin,Jennifer A Bautista,Lynn H Ngo,Monika Deswal,Sadie E Munter,Enrique O Martinez,Khamal A Anglin,Mariela D Romero,Jacqueline Tavs,Paulina R Rugart,Jessica Y Chen,Hannah M Sans,Victoria W Murray,Payton K Ellis,Kevin C Donohue,Jonathan A Massachi,Jacob O Weiss,Irum Mehdi,Jesus Pineda-Ramirez,Alex F Tang,Megan Wenger,Melissa Assenzio,Yan Yuan,Melissa Krone,Rachel L Rutishauser,Isabel Rodriguez-Barraquer,Bryan Greenhouse,John A Sauceda,Monica Gandhi,Priscilla Y Hsue,Timothy J Henrich,Steven G Deeks,Jeffrey N Martin

DOI: https://doi.org/10.1101/2021.03.11.21252311

2021-03-12

MedRxiv

Abstract:Background: As the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC). Methods: From April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit. Results: We have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits. Conclusion: Among a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E. Davis,Gina S. Assaf,Lisa McCorkell,Hannah Wei,Ryan J. Low,Yochai Re'em,Signe Redfield,Jared P. Austin,Athena Akrami

DOI: https://doi.org/10.1016/j.eclinm.2021.101019

IF: 15.1

2021-08-01

EClinicalMedicine

Abstract:BackgroundA significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.MethodsWe conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.FindingsFor the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.InterpretationPatients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.FundingAll authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).
Pediatric Long COVID Subphenotypes: An EHR-based study from the RECOVER program

Vitaly Lorman,L Charles Bailey,Xing Song,Suchitra Rao,Mady Hornig,Levon Utidjian,Hanieh Razzaghi,Asuncion Mejias,John Erik Leikauf,Seuli Bose Brill,Andrea Allen,H Timothy Bunnell,Cara Reedy,Abu Saleh Mohammad Mosa,Benjamin D Horne,Carol Reynolds Geary,Cynthia H Chuang,David A Williams,Dimitri A Christakis,Elizabeth A Chrischilles,Eneida A Mendonca,Lindsay G Cowell,Lisa MocCorkell,Mei Liu,Mollie R Cummins,Ravi Jhaveri,Saul Blecker,Christopher B Forrest

DOI: https://doi.org/10.1101/2024.09.17.24313742

2024-09-18

Abstract:Pediatric Long COVID has been associated with a wide variety of symptoms, conditions, and organ systems, but distinct clinical presentations, or subphenotypes, are still being elucidated. In this exploratory analysis, we identified a cohort of pediatric (age <21) patients with evidence of Long COVID and no pre-existing complex chronic conditions using electronic health record data from 38 institutions and used an unsupervised machine learning-based approach to identify subphenotypes. Our method, an extension of the Phe2Vec algorithm, uses tens of thousands of clinical concepts from multiple domains to represent patients' clinical histories to then identify groups of patients with similar presentations. The results indicate that cardiorespiratory presentations are most common (present in 54% of patients) followed by subphenotypes marked (in decreasing order of frequency) by musculoskeletal pain, neuropsychiatric conditions, gastrointestinal symptoms, headache, and fatigue.

Pediatrics
A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Michael C Sneller,C Jason Liang,Adriana R Marques,Joyce Y Chung,Sujata M Shanbhag,Joseph R Fontana,Haniya Raza,Onyi Okeke,Robin L Dewar,Bryan P Higgins,Katie Tolstenko,Richard W Kwan,Kathleen R Gittens,Catherine A Seamon,Genevieve McCormack,Jacob S Shaw,Grace M Okpali,Melissa Law,Krittin Trihemasava,Brooke D Kennedy,Victoria Shi,J Shawn Justement,Clarisa M Buckner,Jana Blazkova,Susan Moir,Tae-Wook Chun,H Clifford Lane

DOI: https://doi.org/10.7326/M21-4905

Abstract:Background: A substantial proportion of persons who develop COVID-19 report persistent symptoms after acute illness. Various pathophysiologic mechanisms have been implicated in the pathogenesis of postacute sequelae of SARS-CoV-2 infection (PASC). Objective: To characterize medical sequelae and persistent symptoms after recovery from COVID-19 in a cohort of disease survivors and controls. Design: Cohort study. (ClinicalTrials.gov: NCT04411147). Setting: National Institutes of Health Clinical Center, Bethesda, Maryland. Participants: Self-referred adults with laboratory-documented SARS-CoV-2 infection who were at least 6 weeks from symptom onset were enrolled regardless of presence of PASC. A control group comprised persons with no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, recruited regardless of their current health status. Both groups were enrolled over the same period and from the same geographic area. Measurements: All participants had the same evaluations regardless of presence of symptoms, including physical examination, laboratory tests and questionnaires, cognitive function testing, and cardiopulmonary evaluation. A subset also underwent exploratory immunologic and virologic evaluations. Results: 189 persons with laboratory-documented COVID-19 (12% of whom were hospitalized during acute illness) and 120 antibody-negative control participants were enrolled. At enrollment, symptoms consistent with PASC were reported by 55% of the COVID-19 cohort and 13% of control participants. Increased risk for PASC was noted in women and those with a history of anxiety disorder. Participants with findings meeting the definition of PASC reported lower quality of life on standardized testing. Abnormal findings on physical examination and diagnostic testing were uncommon. Neutralizing antibody levels to spike protein were negative in 27% of the unvaccinated COVID-19 cohort and none of the vaccinated COVID-19 cohort. Exploratory studies found no evidence of persistent viral infection, autoimmunity, or abnormal immune activation in participants with PASC. Limitations: Most participants with COVID-19 had mild to moderate acute illness that did not require hospitalization. The prevalence of reported PASC was likely overestimated in this cohort because persons with PASC may have been more motivated to enroll. The study did not capture PASC that resolved before enrollment. Conclusion: A high burden of persistent symptoms was observed in persons after COVID-19. Extensive diagnostic evaluation revealed no specific cause of reported symptoms in most cases. Antibody levels were highly variable after COVID-19. Primary funding source: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs

Shawn T O'Neil,Charisse Madlock-Brown,Kenneth J Wilkins,Brenda M McGrath,Hannah E Davis,Gina S Assaf,Hannah Wei,Parya Zareie,Evan T French,Johanna Loomba,Julie A McMurry,Andrea Zhou,Christopher G Chute,Richard A Moffitt,Emily R Pfaff,Yun Jae Yoo,Peter Leese,Robert F Chew,Michael Lieberman,Melissa A Haendel,N3C Consortium,RECOVER Consortium

DOI: https://doi.org/10.1101/2023.09.11.23295259

2024-06-11

Abstract:Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long-COVID, encompasses a variety of complex and varied outcomes following COVID-19 infection that are still poorly understood. We clustered over 600 million condition diagnoses from 14 million patients available through the National COVID Cohort Collaborative (N3C), generating hundreds of highly detailed clinical phenotypes. Assessing patient clinical trajectories using these clusters allowed us to identify individual conditions and phenotypes strongly increased after acute infection. We found many conditions increased in COVID-19 patients compared to controls, and using a novel method to associate patients with clusters over time, we additionally found phenotypes specific to patient sex, age, wave of infection, and PASC diagnosis status. While many of these results reflect known PASC symptoms, the resolution provided by this unprecedented data scale suggests avenues for improved diagnostics and mechanistic understanding of this multifaceted disease.

Infectious Diseases (except HIV/AIDS)
Identifying Post-Acute Sequelae of SARS-CoV-2 Among Children in New York State Medicaid Managed Care

Philip M. DiMura,Victoria L. Wagner,Tom W. Robertson,Meng Wu,Mary Beth Conroy,Raina Josberger

DOI: https://doi.org/10.1007/s10900-024-01363-4

2024-08-27

Journal of Community Health

Abstract:Persons who contract COVID-19 are at risk of developing post-acute sequelae of SARS-CoV-2 (PASC). The objective of this study was to describe the incidence of PASC in a pediatric Medicaid population. Using a retrospective cohort of children enrolled in New York State Medicaid Managed Care we compared incident diagnoses between children with a positive laboratory test for SARS-CoV-2 in 2021 to children without a positive test in 2021 and children with a viral respiratory diagnosis in 2019. Logistic regression models estimated adjusted odds ratios using the Cohen's d statistic to assess the strength of associations. Most unadjusted incidence of clinical outcomes were less than 1% for all cohorts. Relative to the 2021 comparison cohort, significant increases among SARS-CoV-2 cases were observed in sequela of infectious disease conditions, general signs and symptoms, and pericarditis and pericardial disease and for the 2019 comparison, sequela of infectious disease conditions and suicidal ideation. However, associations were mostly determined to be weak or marginal. In this low socioeconomic status pediatric population, incidence of new clinical sequelae was low with mostly weak or marginal increases associated with SARS-CoV-2 infection. Though the incidence was low, some outcomes may be severe. Observed associations may have been impacted by pandemic behavior modification including social distancing policies.

public, environmental & occupational health,health policy & services
Advances in molecular farming: key technologies, scaled up production and lead targets.

H. Daniell,S. Streatfield,E. Rybicki

DOI: https://doi.org/10.1111/pbi.12478

IF: 13.8

2015-10-01

Plant Biotechnology Journal

Abstract:The field of molecular farming has experienced something of a rollercoaster ride since its inception two and a half decades ago. Realization of the potential for molecular farming followed quickly after the development of technologies in the 1980s to introduce recombinant DNA into plants, with a patent application describing edible vaccines (Curtiss and Cardineau, 1988), and the literature describing the potential for plant-produced antibodies and vaccines (Haq et al., 1995; Hiatt et al., 1989; Usha et al., 1993). The development and refinement of expression technologies for transgenic and transient systems, along with application of these approaches to a wide variety of target molecules produced in a range of model and crop species, were reflected in a flurry of literature and patents over the next decade. Early reports were followed by technology and product development efforts in established agricultural biotechnology companies and newly founded companies focused on molecular farming, with some lead candidates entering early phase clinical trials, recalled in this issue by Arntzen (2015). In parallel, the first patent on chloroplast genetic engineering (Daniell and McFadden, 1988) demonstrated the system’s potential advantages for high-level leaf-based expression and transgene containment via maternal inheritance, with the first vaccine antigen expressed over a decade later (Daniell et al., 2001). However, despite these advances, a combination of non-competitive yields in transgenic plants engineered via the nuclear genome compared to other established recombinant technologies, limited capital for scale-up and clinical product development, regulatory concerns over field production and the need to adapt the technology to conform to the rigorous reproducibility and standardization requirements for vaccines and therapeutics, resulted in most commercial efforts retrenching or terminating. Nevertheless, several significant programmes remained afloat both in academic laboratories and in industry, largely supported by government and charitable foundation grants, due to their long-term potential to combat diseases at reduced cost in developing countries and to react rapidly to emerging bioterror threats. Together with unmet healthcare needs and the high price of biopharmaceuticals, this maintained interest in the field and allowed for the honing of expression technologies, scaling up of processes and exploration of new approaches to improve efficacy. As a result, the last few years have seen some lead candidate molecules progress into later stage clinical trials, pilot and commercial-scale facilities come online and perhaps most significantly, pharmaceutical companies begin to invest significantly in plant-based technologies thorough buyouts and partnerships. The recent application of plant-produced antibodies to treat patients that had contracted Ebola virus disease has also highlighted the technology to the general public. This special issue reviews many of the most important recent advances in the field, together with key products and expression technologies. With one plant-produced therapeutic on the market and several other vaccine and therapeutic candidates in later stage clinical trials, there is considerable optimism that the field is starting to give returns on its early promise. To kick off this special edition, one of the pioneers in the field, Charles Arntzen, provides a historical perspective of plant-made vaccines and therapeutics and relays his experiences with plant-based products developed for oral delivery (Arntzen, 2015). Because of uncertain funding for clinical development of recombinant plant-made vaccine antigens against infectious diseases, it is no surprise that the first FDA approved plant-made biopharmaceutical (PMB) treats a genetic/metabolic disorder (Fox, 2012). Therefore, Kwon and Daniell in this issue provide a brief overview of recent advances in oral delivery of several PMBs to treat major metabolic/genetic disorders including Alzheimer’s disease, diabetes, hypertension and retinopathy. Yet another major advancement in this field is the use of biopharmaceuticals made in chloroplasts of edible plant cells for suppression of toxic antibodies that are produced in response to injected protein drugs, with industrial production supported by a major pharmaceutical company (Su et al., 2015a). In addition, Su et al. (2015b) report significant suppression of GAA-specific inhibitory antibody in Pompe mice, even with a very low oral dose of GAA bioencapsulated in plant cells, further demonstrating the importance of oral tolerance induction. Although FDA approved glucocerebrosidase made in carrot cells is an injectable product, Shaaltiel et al. (2015) in this issue demonstrate the concept of oral delivery of this PMB. Takaiwa et al. (2015) then review recent advances in the expression of several antigens in rice seeds for immunotherapy against infectious, allergic and autoimmune diseases. Chan and Daniell (2015) in the next review point out the challenges in advancing vaccine antigens made in plant cells towards clinical development; they emphasize mechanistic aspects of immunity versus tolerance and provide several examples for combining the use of highly expressing chloroplast technology with carriers that bind receptors in the gastrointestinal tract to more precisely deliver target molecules. Plant-based oral vaccines are particularly attractive for veterinary applications, where there is considerable pressure to keep costs low, but regulatory hurdles are less stringent than those for human products. To this end, Ruiz et al. (2015) review recent advances with plant-made bovine vaccines. Since the inception of molecular farming in the early 1990s, antibodies and engineered fragments and fusions thereof have constituted one of the lead product areas, and plant-produced antibodies have received particular attention for engineering post-translational modifications (Schahs et al., 2007). To reflect the application of novel engineering technologies in plant systems, Wycoff et al. (2015) recount the engineering and expression of immunoadhesins in plants. The maturation of antibody production technology in transgenic plants is addressed by Sack et al. (2015), who describe the development of good manufacturing practices (GMP) for the production of an anti-human immunodeficiency virus monoclonal antibody, and by Ma et al. (2015), who recount the regulatory approval path and clinical testing of this antibody. The most striking improvements in target expression levels and associated product yields over the last fifteen years have come from the development and widespread application of transient expression technologies, some of the most effective of which combine aspects of binary and virus-derived vectors, as reviewed here by Peyret and Lomonossoff (2015). Such transient technologies have been particularly attractive in developing targets against emerging and re-emerging infections and bioterror threats, reviewed by Streatfield et al. (2015). A transient virus vector-based expression approach has also been applied to the anti-HIV microbicide griffithsin, and Fuqua et al. (2015) review progress with this particularly cost-sensitive molecule in the light of alternative expression technologies. Robert et al. (2015) then report on leaf proteome rebalancing to enrich for a transiently expressed recombinant target in vivo, and Holtz et al. (2015) provide an overview of the construction and application of a commercial-scale production facility developed for plant-based transient expression systems. Although whole plant systems have received the most attention, they are also the most distinct from established microbial and mammalian cell production technologies. It is therefore not surprising that the first plant-based human therapeutic to get to market was produced in cell culture. In this issue, Reski et al. (2015) provide an overview of a moss bioreactor system, and Tekoah et al. (2015) recount directing taliglucerase alfa to market and the development of further products in plant cell culture. Finally, Paul et al. (2015) provide an overview of product development experiences of several of the major commercial ventures in the field, drawn from interviews with principal players. It is hoped that this special issue will provide both historical context and spotlight important new developments in the field of molecular farming as it progresses further products to market and gains more widespread acceptance in the biopharmaceutical industry.
Alpha-actinin-2, a cytoskeletal protein, binds to angiogenin.

Huajun Hu,Xiangwei Gao,Yishan Sun,Jiliang Zhou,Min Yang,Zhengping Xu

DOI: https://doi.org/10.1016/J.BBRC.2005.01.158

2005-04-08

Abstract:
Prevalence and Risk Factor for Long COVID in Children and Adolescents: A Meta-Analysis and Systematic Review

Yong-Bo Zheng,Na Zeng,Kai Yuan,Shan-Shan Tian,Ying-Bo Yang,Nan Gao,Xuan Chen,An-Yi Zhang,Alexandra L. Kondratiuk,Pei-Pei Shi,Fang Zhang,Jie Sun,Jing-Li Yue,Xiao Lin,Le Shi,Ajit Lalvani,Jie Shi,Yan-Ping Bao,Lin Lu

DOI: https://doi.org/10.1016/j.jiph.2023.03.005

IF: 7.537

2023-01-01

Journal of Infection and Public Health

Abstract:BACKGROUND:Millions of COVID-19 pediatric survivors are facing the risk of long COVID after recovery from acute COVID-19. The primary objective of this study was to systematically review the available literature and determine the pooled prevalence of, and risk factors for long COVID among the pediatric survivors. METHODS:Studies that assessed the prevalence of, or risk factors associated with long COVID among pediatric COVID-19 survivors were systematically searched in PubMed, Embase, and Cochrane Library up to December 11th, 2022. Random effects model was performed to estimate the pooled prevalence of long COVID among pediatric COVID-19 patients. Subgroup analyses and meta-regression on the estimated prevalence of long COVID were performed by stratification with follow-up duration, mean age, sex ratio, percentage of multisystem inflammatory syndrome, hospitalization rate at baseline, and percentage of severe illness. RESULTS:Based on 40 studies with 12,424 individuals, the pooled prevalence of any long COVID was 23.36 % ([95 % CI 15.27-32.53]). The generalized symptom (19.57 %, [95 % CI 9.85-31.52]) was reported most commonly, followed by respiratory (14.76 %, [95 % CI 7.22-24.27]), neurologic (13.51 %, [95 % CI 6.52-22.40]), and psychiatric (12.30 %, [95% CI 5.38-21.37]). Dyspnea (22.75 %, [95% CI 9.38-39.54]), fatigue (20.22 %, [95% CI 9.19-34.09]), and headache (15.88 %, [95 % CI 6.85-27.57]) were most widely reported specific symptoms. The prevalence of any symptom during 3-6, 6-12, and> 12 months were 26.41 % ([95 % CI 14.33-40.59]), 20.64 % ([95 % CI 17.06-24.46]), and 14.89 % ([95 % CI 6.09-26.51]), respectively. Individuals with aged over ten years, multisystem inflammatory syndrome, or had severe clinical symptoms exhibited higher prevalence of long COVID in multi-systems. Factors such as older age, female, poor physical or mental health, or had severe infection or more symptoms were more likely to have long COVID in pediatric survivors. CONCLUSIONS:Nearly one quarter of pediatric survivors suffered multisystem long COVID, even at 1 year after infection. Ongoing monitoring, comprehensive prevention and intervention is warranted for pediatric survivors, especially for individuals with high risk factors.

1 PHYSICAL GROWTH DURING THE FIRST YEAR OF LIFE OF INFANTS A LONGITUDINAL STUDY IN ONE RURAL AND ONE URBAN AREA OF HANOI VIETNAM

Understanding Post-Acute Sequelae of SARS-CoV-2 Infection Through Data-Driven Analysis with the Longitudinal Electronic Health Records: Findings from the RECOVER Initiative

Postacute Sequelae of SARS-CoV-2 in Children

Characterizing Long COVID in Children and Adolescents

Symptoms and risk factors for long COVID in non-hospitalized adults

Risk Factors Associated with Post-Acute Sequelae of SARS-CoV-2 in an EHR Cohort: A National COVID Cohort Collaborative (N3C) Analysis as part of the NIH RECOVER program

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study

Attributes and predictors of long COVID

X-ray treatment of otosalpingitis.

Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Pediatric Long COVID Subphenotypes: An EHR-based study from the RECOVER program

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs

Identifying Post-Acute Sequelae of SARS-CoV-2 Among Children in New York State Medicaid Managed Care

Advances in molecular farming: key technologies, scaled up production and lead targets.

Alpha-actinin-2, a cytoskeletal protein, binds to angiogenin.

Prevalence and Risk Factor for Long COVID in Children and Adolescents: A Meta-Analysis and Systematic Review